These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 27996332

  • 1. DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers.
    Lee AW, Jordanov E, Boisnard F, Marshall GS.
    Expert Rev Vaccines; 2017 Feb; 16(2):85-92. PubMed ID: 27996332
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F, Boisnard F, Thomas S, Sadorge C, Borrow R, PRI02C study group.
    Vaccine; 2017 Jun 27; 35(30):3764-3772. PubMed ID: 28583305
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA, Tapiéro B, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee A, Li M, Tomovici A.
    Pediatr Infect Dis J; 2014 Jan 27; 33(1):73-80. PubMed ID: 24346596
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP, Abu-Elyazeed R, Cheuvart B, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2019 Jan 27; 15(4):809-821. PubMed ID: 30444673
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1505-1515. PubMed ID: 28340322
    [Abstract] [Full Text] [Related]

  • 6. Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine.
    Xu J, Stek JE, Ziani E, Liu GF, Lee AW.
    Pediatr Infect Dis J; 2019 Apr 03; 38(4):439-443. PubMed ID: 30882742
    [Abstract] [Full Text] [Related]

  • 7. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA, Assudani D, Kuriyakose S, Van Der Meeren O.
    Hum Vaccin Immunother; 2014 Apr 03; 10(10):2795-8. PubMed ID: 25483640
    [Abstract] [Full Text] [Related]

  • 8. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
    Zepp F, Knuf M, Heininger U, Jahn K, Collard A, Habermehl P, Schuerman L, Sänger R.
    Vaccine; 2004 Jun 02; 22(17-18):2226-33. PubMed ID: 15149781
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants.
    Lalwani SK, Agarkhedkar S, Sundaram B, Mahantashetti NS, Malshe N, Agarkhedkar S, Van Der Meeren O, Mehta S, Karkada N, Han HH, Mesaros N.
    Hum Vaccin Immunother; 2017 Jan 02; 13(1):120-127. PubMed ID: 27629913
    [Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.
    Tapiéro B, Halperin SA, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee AW, Li M, Tomovici A.
    Pediatr Infect Dis J; 2013 Jan 02; 32(1):54-61. PubMed ID: 23241989
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Differences by sex in IgG levels following infant and childhood vaccinations: An individual participant data meta-analysis of vaccination studies.
    Boef AGC, van der Klis FRM, Berbers GAM, Buisman AM, Sanders EAM, Kemmeren JM, van der Ende A, de Melker HE, Rots NY, Knol MJ.
    Vaccine; 2018 Jan 08; 36(3):400-407. PubMed ID: 29223483
    [Abstract] [Full Text] [Related]

  • 14. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
    López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B Chir S, Zambrano B.
    Pediatr Infect Dis J; 2017 Nov 08; 36(11):e272-e282. PubMed ID: 28719500
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA, Tapiero B, Diaz-Mitoma F, Law BJ, Hoffenbach A, Zappacosta PS, Radley D, McCarson BJ, Martin JC, Brackett LE, Boslego JW, Hesley TM, Bhuyan PK, Silber JL.
    Vaccine; 2009 Apr 28; 27(19):2540-7. PubMed ID: 19124057
    [Abstract] [Full Text] [Related]

  • 16. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
    Quiambao B, Van Der Meeren O, Kolhe D, Gatchalian S.
    Hum Vaccin Immunother; 2012 Mar 28; 8(3):347-54. PubMed ID: 22330958
    [Abstract] [Full Text] [Related]

  • 17. A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age.
    Thollot F, Scheifele D, Pankow-Culot H, Cheuvart B, Leyssen M, Ulianov L, Miller JM.
    Pediatr Infect Dis J; 2014 Dec 28; 33(12):1246-54. PubMed ID: 25037033
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L, Spanish DTaP-HBV-IPV-097 Study Group.
    Pediatr Infect Dis J; 2006 Aug 28; 25(8):713-20. PubMed ID: 16874171
    [Abstract] [Full Text] [Related]

  • 19. Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule.
    Martinón-Torres F, Salamanca de la Cueva I, Horn M, Westerholt S, Bosis S, Meyer N, Cheuvart B, Virk N, Jakes RW, Duchenne M, Van den Steen P.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2342630. PubMed ID: 38687024
    [Abstract] [Full Text] [Related]

  • 20. DTaP5-HBV-IPV-Hib pediatric hexavalent combination vaccine for use in children from 6 weeks through to 4 years of age.
    Obando-Pacheco P, Rivero-Calle I, Raguindin PF, Martinón-Torres F.
    Expert Rev Vaccines; 2019 Nov 31; 18(11):1115-1126. PubMed ID: 31697185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.